Stay updated on Sparsentan in IgA Nephropathy: Clinical Trial
Sign up to get notified when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.

Latest updates to the Sparsentan in IgA Nephropathy: Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no visible changes to core study content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded new trial locations across the United States, Australia, and Europe and removed several existing locations, altering the geographic availability of study sites. This affects where participants can enroll and access the trial.SummaryDifference3%

- Check53 days agoChange DetectedPublications section now states that PubMed publications are automatically filled, and the page revision is updated to v3.3.2.SummaryDifference0.0%

- Check60 days agoChange DetectedRemoval of an administrative funding-status notice from the page. The study details, eligibility criteria, primary and secondary outcomes, and listed locations remain unchanged.SummaryDifference0.1%

- Check75 days agoChange DetectedNo significant changes were detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.2%

- Check103 days agoChange DetectedAdded a site operation notice, introduced a new disease resource (IgA glomerulonephritis), and updated revision to v3.2.0 while removing v3.1.0.SummaryDifference2%

Stay in the know with updates to Sparsentan in IgA Nephropathy: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sparsentan in IgA Nephropathy: Clinical Trial page.